While INI1-deficient lung cancer rarely coexists with EGFR, ALK, or other oncogenic driver mutations, comprehensive genetic profiling (CGP) remains essential for guiding treatment decisions, particularly in advanced-stage patients. This evidence concerns the gene SMARCB1 and lung cancer.